WednesdayJun 29, 2022 2:48 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Focused on International Strategy to Reach ‘Larger Consumer Base’

Flora Growth Corp. (NASDAQ: FLGC) CEO Luis Merchan is quoted in a recent article saying, “International growth is a key objective of our company’s strategy.” Earlier this year, the company completed the acquisition of 100% equity interests of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, in a move by Flora Growth to explore global expansion opportunities and increase its customer database. The article reads: “By mid-May 2022, Flora Growth had already announced the expansion of its operational footprint in Europe and the United Kingdom to further its international growth strategy… In what marks…

Continue Reading

WednesdayJun 29, 2022 2:28 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Stand Distinct, Push Brand

Lexaria Bioscience Corp. (NASDAQ: LEXX) acknowledges consumers’ shift away from smoking cigarettes to nicotine alternatives, which has resulted in the growth of the nicotine pouch and nicotine replacement therapy (“NRT”) markets. Through its patented DehydraTECH technology, Lexaria looks to tap into the multibillion-dollar nicotine alternatives industry and stamp its position. “In a move that sought to prove DehydraTECH’s superiority, Lexaria conducted an oral nicotine absorption study in 2021. The research showed that Lexaria’s DehydraTECH-nicotine delivered via an oral pouch product dispensed enough nicotine levels in blood plasma in four minutes, as concentration-matched controls did in 45 minutes. In addition, peak…

Continue Reading

TuesdayJun 21, 2022 3:13 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the signing of two agreements with Atlanta-based BevNology LLC. According to the update, the first manufacturing operating agreement expands production capabilities for Lexaria’s own growing list of business-to-business (“B2B”) clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands. A new, state-of-the-art processing facility custom-built by BevNology is operational that increases and broadens production capacity and is currently serving Lexaria’s corporate clients. The second commercial license agreement empowers BevNology to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol (“CBD”) under BevNology and…

Continue Reading

TuesdayJun 21, 2022 1:20 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Congratulates Colombia’s President-Elect Gustavo Petro

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, congratulates Gustavo Petro and the Humane Colombia Party on their victory in Sunday’s presidential runoff election in Colombia. “We would like to congratulate President-Elect Gustavo Petro on his victory, and we look forward to working with the new government to continue Colombia’s progressive momentum in the global cannabis industry,” said Luis Merchan, Flora’s chairman and CEO. “We are encouraged by President-Elect Petro’s stance on seeing Colombia become a leader in the legal cannabis industry, and we are hopeful for progressive legislation that will allow…

Continue Reading

FridayJun 17, 2022 3:23 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Ground-Breaking Studies Opening ‘Doors Previously Closed to Disruptive New Technology’

Lexaria Bioscience Corp. (NASDAQ: LEXX) understands the shortcomings of orally administered drugs and is developing DehydraTECH(TM), a drug delivery technology that solves challenges such as poor water solubility and membrane permeability, limited absorption and unwanted tastes. “The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications… Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of…

Continue Reading

ThursdayJun 16, 2022 2:36 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces $5M Share Repurchase Program

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors has authorized the repurchase of up to $5 million of its outstanding common shares as market conditions and the company’s liquidity warrant. “We believe that the potential to repurchase our shares at these levels represents a compelling opportunity to deploy available cash to drive shareholder value,” said Luis Merchan, Flora’s chairman and CEO. “Flora continues to move assertively to execute its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expenses. We are confident…

Continue Reading

TuesdayJun 14, 2022 2:53 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well as the potential these substances have in addressing various skin conditions. The study used a recognized in vitro model of human keratinocytes to analyze how specific cannabinoids interacted with cannabinoid receptors and other endocannabinoid system…

Continue Reading

FridayJun 10, 2022 12:44 pm

CannabisNewsBreaks – Flora Growth Corp.’s (NASDAQ: FLGC) Completion of Key Milestones Position It for Success

Flora Growth Corp. (NASDAQ: FLGC) recently announced financial and operating results for the 2021 fiscal year that show the success of its efforts as revenues and profits begin what is expected to be a rapid climb. “The year-end financial results show about $9 million in revenues, which is ‘significantly higher’ than those reported the prior year before the law change and Flora’s IPO launch on the Nasdaq Capital Market. The report maintains the company’s outlook for ending 2022 with revenues of $35 million to $45 million, which would be growth of between 288% and 400% over 2021. Much of Flora’s…

Continue Reading

ThursdayJun 09, 2022 2:14 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its launch of B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly owned subsidiary, BayMedica LLC. “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” said Shane Johnson, MD, SVP and general manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike.…

Continue Reading

WednesdayJun 08, 2022 12:25 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977